|
Oct 17
|
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
|
|
Oct 17
|
Kezar Life Sciences Rejects Concentra Biosciences Takeover Bid, Adopts Rights Plan
|
|
Oct 17
|
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
|
|
Oct 17
|
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
|
|
Oct 15
|
What Makes Kezar Life Sciences (KZR) a New Buy Stock
|
|
Oct 10
|
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
|
|
Dec 18
|
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth
|